欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 岛国精品视频在线观看免费 | 亚洲精品欧| 国产欧美日韩精品性爱 | 91免费人成网站在线观看18 | 久久国产精 | 亚洲一区二区性爱无码 | av在线激情网站 | 加勒比一本大道香蕉av | 院线大片抢先看 | 国产刺激视频在线观看 | 国产精品涩涩涩视频网站 | 一区二区三区动漫成人在线观看 | 国产午夜福利片在线观看 | 2025久久国自产拍 | 国产一本视频在线播放 | 亚洲av日韩精品久久久久 | 亚洲成a人片在线观看国产 亚洲成a人片在线观看天堂无码 | 免费的污污的网站在线观看 | 国产一区二区自拍视频 | www.黄网| 国产在线久欧美视频 | 国产偷久久久精品专区 | 精品亚洲aⅴ导航 | 日韩亚洲人成网站在线播放 | 91干屁 | 动漫精品一区二 | 日本不卡一二三区 | 久久天堂日韩av线 | 久久久99精品免费观看 | 国产特级毛片aaaaaa高清 | 国产精品蜜桃久久久久 | 午夜小视频在线观看 | 午夜亚洲av日韩av无码大全 | 国产精品欧美亚洲 | 欧美人与禽z0zo牲伦交 | 欧美亚洲综合另类在线观看 | 国产成年无码v片 | 91福利国产视频 | 国产精品国产 | 2025给个网站好人有好报 | 精品在线看 |